NGL Fine Chem Ltd (NGLFINE) — shareholding pattern, promoter holding, financials and share price
About NGL Fine Chem Ltd (NGLFINE)
NGL Fine Chem Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as NGLFINE and on the BSE under scrip code 524774. Its ISIN is INE887E01022.
Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health. [1]
NGL Fine-Chem Limited is an integrated manufacturer of pharmaceutical APIs, primarily focused on veterinary APIs, plus human APIs, intermediates and a small finished-dosage portfolio, operating three state-of-the-art facilities in Tarapur and Navi Mumbai with WHO-GMP and other international accreditations and a large global customer base.
Q3FY26 financials show accelerating recovery with revenue from operations at ₹127.51 crore (up 43% YoY) and 9MFY26 revenue at ₹351.89 crore (up 28.7% YoY); EBITDA improved sharply to ₹22.31 crore in Q3 with a 17.5% margin, reflecting easing raw material costs and operational efficiencies that materially lifted profitability.
Listed peers in Pharmaceuticals: Venus Remedies Ltd, Ind-Swift Laboratories Ltd, Sakar Healthcare Ltd, Hester Biosciences Ltd, Windlas Biotech Ltd, Amrutanjan Health Care Ltd.
Valuation & Returns
10 Jul 2026At ₹3,201.7 a share on 10 Jul 2026, NGL Fine Chem Ltd (NGLFINE) was valued at a price-to-earnings ratio of 41.17x against an industry P/E of 36.41x and a price-to-book of 7x on a book value of ₹457.16 per share as of Mar 2025. Solomo computes return on equity of 17.01% and return on capital employed of 19.05% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 41.17x
- Industry P/E
- 36.41x
- P/B
- 7x
- EPS (TTM)
- ₹77.78
- Book value / share
- ₹457.16
- ROE
- 17.01%
- ROCE
- 19.05%
- ROA
- 11.09%
- Debt / equity
- 0.26x
- Dividend yield
- 0.05%
- EBITDA margin
- 17.43%
- 52-week range
- ₹1,180 – ₹3,321.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, NGL Fine Chem Ltd (NGLFINE) reported revenue of ₹501 crore, net profit of ₹48 crore and earnings per share of ₹77.91. That compares with revenue of ₹368 crore and net profit of ₹21 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹149 crore and net profit ₹13 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 318 | 278 | 339 | 368 | 501 |
| Net profit (₹ cr) | 50 | 20 | 41 | 21 | 48 |
| EPS (₹) | 80.77 | 33.18 | 66.88 | 34.19 | 77.91 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 14.81% | 18.75% | 4.08% | 8.73% |
| Profit growth | 5.29% | 11.33% | -29.73% | -48.89% |
| Stock price CAGR | 29% | 1% | 14% | 115% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 72.49% of NGL Fine Chem Ltd (NGLFINE) (down 0.25 pp QoQ), foreign institutional investors (FII) hold 0.05% and domestic institutional investors (DII) hold 0.02%. Market capitalisation was ₹1,978 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2002.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 72.49% | - | 0.05% | 0.02% | 27.51% |
| Mar 2026 | 72.74% | - | 0.03% | - | 27.26% |
| Dec 2025 | 72.74% | - | - | - | 27.26% |
| Sep 2025 | 72.74% | - | 0% | - | 27.26% |
| Jun 2025 | 72.74% | - | 0% | 0% | 27.26% |
| Mar 2025 | 72.74% | - | 0% | 0% | 27.26% |
| Dec 2024 | 72.74% | - | 0.04% | 0% | 27.26% |
| Sep 2024 | 72.74% | - | 0.02% | 0% | 27.26% |